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Abstract
Background: Deficient nucleotide excision repair (NER) activity causes a variety of autosomal recessive diseases
including xeroderma pigmentosum (XP) a disorder which pre-disposes to skin cancer, and the severe multisystem
condition known as Cockayne syndrome (CS). In view of the clinical overlap between NER-related disorders, as well as
the existence of multiple phenotypes and the numerous genes involved, we developed a new diagnostic approach
based on the enrichment of 16 NER-related genes by multiplex amplification coupled with next-generation sequencing
(NGS).
Methods: Our test cohort consisted of 11 DNA samples, all with known mutations and/or non pathogenic SNPs in
two of the tested genes. We then used the same technique to analyse samples from a prospective cohort of 40
patients. Multiplex amplification and sequencing were performed using AmpliSeq protocol on the Ion Torrent PGM
(Life Technologies).
Results: We identified causative mutations in 17 out of the 40 patients (43 %). Four patients showed biallelic mutations
in the ERCC6(CSB) gene, five in the ERCC8(CSA) gene: most of them had classical CS features but some had very mild and
incomplete phenotypes. A small cohort of 4 unrelated classic XP patients from the Basque country (Northern Spain)
revealed a common splicing mutation in POLH (XP-variant), demonstrating a new founder effect in this population.
Interestingly, our results also found ERCC2(XPD), ERCC3(XPB) or ERCC5(XPG) mutations in two cases of UV-sensitive
syndrome and in two cases with mixed XP/CS phenotypes.
Conclusions: Our study confirms that NGS is an efficient technique for the analysis of NER-related disorders on a
molecular level. It is particularly useful for phenotypes with combined features or unusually mild symptoms. Targeted
NGS used in conjunction with DNA repair functional tests and precise clinical evaluation permits rapid and cost-effective
diagnosis in patients with NER-defects.
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Background
Nucleotide excision repair (NER) is a multistep DNA repair
process in which a broad spectrum of DNA lesions are re-
moved in two stages - one acting genome-wide (GG-NER)
and the other on actively transcribed strands (TC-NER) [1].
Despite a common autosomal recessive pattern of inherit-
ance, genetic defects in the NER pathway lead to a broad
variety of clinical conditions, namely: xeroderma pigmento-
sum (XP), trichothiodystrophy (TTD), Cockayne syndrome
(CS) and UV-sensitive syndrome (UVSS) (Table 1). Xero-
derma pigmentosum (Orpha number 910) is a genoder-
matosis characterized by extreme sensitivity to ultraviolet
(UV)-induced changes in the skin and eyes, and multiple
skin cancers. XP patients present sunlight-induced pigmen-
tation changes, a predisposition to skin cancer and in about
30 % of cases neurological degeneration with progressive
cognitive impairment. Classical XP results from defects in
one of seven genes, XPA through to G. XP-variant, charac-
terized by the absence of DNA repair deficits, results from
a deficiency in the translesion synthesis DNA polymerase,
polη [2]. Trichothiodystrophy (Orpha number 33364) is a
very rare heterogeneous group of disorders characterized
by brittle hair with low-sulfur content associated with
neurodevelopmental impairment. The spectrum of symp-
toms observed in TTD patients ranges from mild forms of
the disease, characterized by normal development with brit-
tle hair and scaling skin only, to very severe cases, charac-
terized by high mortality at a young age combined with
severe neurodevelopmental defects. Approximately 50 % of
patients with TTD exhibit marked photosensitivity. These
photosensitive patients are found to be carriers of biallelic
mutations, usually in the ERCC2(XPD) gene, or more rarely
in ERCC3(XPB) or TTDA [3]. All encode for subunits of
the dual function repair/transcription factor II H (TFIIH)
and result in a NER defect, which explains the photosensi-
tivity observed. Amongst the remaining 50 % of non-
photosensitive TTD cases, a minority (about 10 %) carry
biallelic mutations in TTDN1, a ubiquitously expressed
gene thought to play a role in the maintenance of the cell
cycle [4–6]. Cockayne syndrome (Orpha number 191) is a
multisystem disorder characterized by intellectual disability,
microcephaly, severe growth failure, sensory impairment,
peripheral neuropathy and cutaneous photosensitivity [7].
Various degrees of severity have been described, including:
a prenatal-onset form known as cerebro-oculo-facio-skel-
etal (COFS) syndrome (Orpha number 1466), an early-
onset or severe form (CS type II), a “classical” or moderate
form (CS type I) and a mild or late-onset form (CS type
III). The two major genes responsible for the disorder,
ERCC6(CSB) and ERCC8(CSA) were identified in the mid
1990s [8, 9]. More recently, defects in either XPF endo-
nuclease or in its partner ERCC1 have also been associated
with CS [10]. COFS patients show mutations mainly in
ERCC6(CSB) [11, 12], but also in ERCC2(XPD) [13],
ERCC5(XPG) [14–16] and ERCC1 [17]. A few rare cases
show combined features of CS and XP. Some of these
patients present in the neonatal period with severe features
such as in COFS, which leads to early mortality. Others
Table 1 Clinical symptoms of NER-related disorders and more frequently involved genes
Cockayne syndrome COFS syndrome Trichothiodystrophy Xeroderma pigmentosum UV-sensitive syndrome
Growth failure ++ ++ + - -
Microcephaly ++ ++ +/− +/− -
Intellectual disability ++ ++ +/− +/− -
Retinal degeneration + +/− - - -
Cataracts + + + - -
Deafness + +/− +/− - -
Photosensitivity + +/− +/− ++ ++
Brittle hair - - ++ - -
Cancer - - - ++ -
Known involved genes ERCC6(CSB) ERCC6(CSB) ERCC2(XPD) XPC ERCC6(CSB)
ERCC8(CSA) ERCC2(XPD) ERCC3(XPB) ERCC2(XPD) ERCC8(CSA)
ERCC5(XPG) TTD-A XPA UVSSA(KIAA1530)
ERCC1 TTDN1 POLH
ERCC5(XPG)
DDB2(XPE)
ERCC3(XPB)
ERCC1
ERCC4(XPF)
COFS: cerebro-oculo-facio-skeletal syndrome
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have later onset and milder neurological/developmental
abnormalities with XP-like skin lesions which develop in
later life [18–20]. These combined presentations are mainly
linked to mutations in ERCC2(XPD), ERCC3(XPB) or
ERCC5(XPG) [16, 18, 19], but defects in ERCC4 have also
recently been observed [10]. Finally, UV-sensitive syn-
drome (Orpha number 178338) is characterized by isolated
cutaneous photosensitivity without any of the other features
associated with CS, and without the pre-disposition to skin
malignancy as in xeroderma pigmentosum. It has been
linked to mutations in ERCC6(CSB),ERCC8(CSA) and in
the recently identified gene encoding for UV-stimulated
scaffold protein A (UVSSA) [21–23]. Distinct functions of
the CS proteins aside from their role in TC-NER, may
account for the various clinical symptoms of CS and for the
differences between CS and UVSS [24]. Intriguingly, neither
the site nor the nature of the mutation in CSA or CSB
seems to correlate with the clinical differences observed
amongst patients with CS and UVSS [25].
Clinical recognition of NER defects remains challenging,
due to the remarkable heterogeneity and overlap of clinical
symptoms which exists between these conditions (Table 1).
Moreover, the existence of combined forms, such as XP/
CS, further complicates the diagnosis. Historically, the diag-
nosis was confirmed by DNA repair activity testing on pri-
mary fibroblasts, using ‘unscheduled DNA synthesis (UDS)’
to test GG-NER, and ‘recovery of RNA synthesis (RRS)’ to
test TC-NER [26]. More recently, gene identification has
permitted molecular diagnosis of NER related disorders,
using Sanger sequencing of candidate genes. The clinical
presentations, as well as the results of UDS and RRS cellu-
lar tests, are used to guide the investigations towards the
gene involved. However, this gene-by-gene sequential ap-
proach is expensive and time consuming. Our goal was to
develop a single and efficient mutation-screening strategy
for all NER related disorders, and to improve our under-
standing of the clinical spectrum observed. In this study,
we describe our findings, based on the enrichment of 16
genes of the NER pathway by multiplex amplification
coupled with next-generation sequencing (NGS). Our co-
hort included 40 patients referred for suspicion of NER
defects.
Methods
Patients and samples
Initially, the NGS procedure was tested and validated on a
small cohort of 11 patients who had already been screened
for the entire coding sequence of ERCC6(CSB) and/or
ERCC8(CSA) genes. Next, a prospective cohort of 40 con-
secutive patients referred to our lab with suspicion of NER
defects was studied. For all patients, written consent for
genetic testing was obtained, either from adult probands or
from a legal representative in the case of minors.
DNA sample and quality control
Genomic DNA was extracted either from peripheral blood
or fibroblast cultures following standard procedures (QIA-
GEN). DNA concentration and quality were assessed at
each quality-control step using either Nanodrop® 8000,
Qubit® 2.0 fluorometer (Life technologies), or LabChip® GX
(Caliper).
Multiplex amplification
Targeted genomic regions covered exons from the major
isoform of the 16 genes involved in the NER pathway
(Table 2). Exon coordinates were extended to an additional
50 bp in flanking intronic sequences. Entire 5’ and 3’ un-
translated regions were included for ERCC6(CSB) and
ERCC8(CSA) genes only. Primer design for multiplex amp-
lification was performed with Ion AmpliSeq Designer
version 2.2 (reference IAD43922_95, Life Technologies).
The overall targeted regions span 62 kb, amplified in 452
amplicons (length between 125 and 175 bp), and are di-
vided into two pools.
NGS sequencing
NGS library preparation for sequencing of the targeted
genes was performed by multiplex amplification using the
Ion AmpliSeq Library Kit 2.0 (Life Technologies). Individ-
ual samples were then barcoded using Ion Xpress™ Barcode
Adapters 1–16 Kits. The amplified librairies were purified
using Agencourt AMPure XP Beads (Beckman Coulter).
Before library pooling of up to 8 patients, amplified libraries
were validated using the 2100 BioAnalyzer System (Agi-
lent). Emulsion PCR of the pooled library was performed
using the OneTouch™ 2 system (Life Technologies). Enrich-
ment of the template-positive ion sphere particles (ISPs,
containing clonally amplified DNA) was performed using
the Ion OneTouch ES (Life Technologies), according to the
manufacturer’s instructions. The percentage of templated
ISPs compared to total ISPs was estimated using an Ion
Sphere™ Quality Control kit on a Qubit® 2.0 Fluorometer
(Life Technologies). The enriched ISPs were loaded on
either Ion 314 (validation phase only) or Ion 316 chips and
sequenced with an Ion Personal Genome Machine (PGM,
Life Technologies).
NGS bioinformatic analysis: read mapping, variant calling
and filtering
Sequencing data was collected and analyzed by the
Torrent Suite v4.4 (Life Technologies), including base
calling, barcode sorting, alignement to the reference
genome (GRCh37), variant calling and coverage ana-
lysis. Low stringency default parameters for germline
mutations were used on the Variant Caller plugin of the
Ion Torrent Browser with the exception of indel and
multiple nucleotide polymorphism maximum strand
bias that was set to 1.
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DNA sequences were visualized using Alamut Visual
2.7.1 (Interactive Biosoftware). Initial variant filtering
included the removal of frequent variants (minor allele
frequency ≥ 0.01) present either in dbSNP142 [27], in the
Exome Variant Server [28] or in the Exome Aggregation
Consortium (ExAC) [29]. Recurrent variations found in
more than 10 % of the patients in our cohort were also
filtered. Subsequent variant annotation and ranking was
performed using VaRank v1.4.0 [30] configured with Ala-
mut Batch (Interactive biosoftware).
Gap filling and variant confirmation using Sanger
sequencing
Gaps in NGS coverage of the targeted regions (i. e. cover-
age <30X, the threshold recommended in the literature
[31, 32]), were filled with Sanger sequencing for coding
sequences of the ERCC6(CSB) and ERCC8(CSA) genes
only. Variants identified by the NGS approach were
confirmed by Sanger DNA sequencing and familial segre-
gation analyses were performed as extensively as possible.
Sequences were obtained either on 3130xl or 3500 Genetic
Analyzer (Applied Biosystems), aligned with the Sequen-
cing Pilot software (JSI) and compared with the corre-
sponding genomic DNA reference sequence (GRCh37).
Splicing variants were validated by Sanger sequencing on
cDNA obtained by reverse transcription of RNA ex-
tracted from patient’s fibroblasts when available. All
primer sequences are available upon request.
Illumina OminiExpress-24 chips
Samples were processed on Illumina OmniExpress-24 v1
arrays using the Infinium assay as previously described [33],
and results were analyzed using Illumina GenomeStudio
software. Reference standards were set with the Illumina
Genetrain 2.0 algorithm using the 96 samples processed
during the same run. Regions of homozygosity were called
with the Illumina cnvPartition 3.1.6 algorithm, with a min-
imal region size of 1 Mb.
Cell lines and culture conditions
All cells used in our study were human primary fibroblasts
derived from patients. Cells were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) (Ref. 21885–025,
GIBCO) supplemented with 10 % FBS (Ref. 10500–064,
GIBCO) and 1 % Antiseptic-Antimycotic (Ref. 15240–062,
GIBCO) at 37 °C in a humidified atmosphere containing
5 % CO2 until RRS and UDS was initiated.
RRS assay
Cells were plated on coverslips in 6-well plates at a con-
fluency of 7x104 cells per well. After 2 days of growing, cells
were washed with PBS, followed by irradiation with a range
of UV-C doses (6-12-20 J/m2). The non-irradiated plate(s)
acted as references. After UV-irradiation, cells were incu-
bated for 23 h for RNA Synthesis recovery in DMEM
supplemented with FBS. Then, after washing with PBS, cells
were labelled with 5-ethynyl-uridine (EU; Invitrogen) for
2 h. Cells were then washed again with PBS, followed by
Table 2 Genes included in the targeted next generation sequencing strategy
Official gene symbol Legacy name Ref Seq NM # # Exons Size of coding exons (bp) Targeted region size (bp) Theoretical coverage
DDB1 NM_001923.4 27 3423 6,150 94.67 %
DDB2 XPE NM_000107.2 10 1284 2,268 99.03 %
ERCC1 NM_001983.3 10 894 2,102 99.57 %
ERCC2 XPD NM_000400.3 23 2283 4,894 98.12 %
ERCC3 XPB NM_000122.1 15 2349 3,864 99.48 %
ERCC4 XPF NM_005236.2 11 2751 3,862 100.00 %
ERCC5 XPG NM_000123.3 15 3561 5,076 100.00 %
ERCC6 CSB NM_000124.3 21 4482 9,127 99.99 %
ERCC8 CSA NM_000082.3 12 1191 3,256 98.65 %
GTF2H5 TTD-A NM_207118.2 3 216 418 100.00 %
MPLKIP TTDN1 NM_138701.3 2 540 742 100.00 %
POLH NM_006502.2 11 2142 3,152 100.00 %
USP7 NM_003470.2 31 3309 6,440 93.88 %
UVSSA KIAA1530 NM_020894.2 14 2130 3,443 99.07 %
XPA NM_000380.3 6 822 1,428 100.00 %
XPC NM_004628.4 16 2823 4,767 100.00 %
Total 227 34200 58,721
Targeted genomic regions covered coding exons with their intron boundaries (50 pb) from the major isoform of 16 genes involved in NER pathway. 5’ and 3’
untranslated regions (UTR) were included for ERCC6(CSB) and ERCC8(CSA) genes only. The total panel size was 62 kb considering the 3 genes located on sex
chromosomes (SRY, AMELX and AMELY) added as gender internal quality control
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fixation and permeabilization. The last step involved an
azide-coupling reaction and DAPI staining (Click-iT RNA
HCS Assay, Invitrogen). Finally coverslips were washed in
PBS, and mounted on glass slides with Ibidi Mounting
Medium (Biovalley).
Photographs of the cells were taken with a fluorescent
microscope (Imager.Z2) equipped with a CCD camera
(AxioCam, Zeiss). The images were processed and analyzed
with the ImageJ software. At least 50 cells were randomly
selected, and the average nuclear fluorescent intensity was
calculated.
UDS assay
Cells were plated on coverslips in 6-well plates at a con-
fluency of 7x104 cells per well. After 2 days of growing,
cells were washed with PBS, followed by irradiation with a
range of UV-C doses (5-10-15 J/m2), the non-irradiated
plate(s) being the reference. After UV-irradiation, cells
were incubated for 3 h with 5-ethynyl-2’-deoxyuridine
(EdU; Invitrogen) contained in F 10 medium without thy-
midine supplemented with dialyzed FBS and 5-fluoro-2-
deoxyuridine (Fudr; Sigma). After washing with PBS,
cells were then incubated for 15 min in full normal
medium (F 10 + antibiotics + 15 % FBS) complemented
with cold thymidine (thymidine 5’ triphosphate; Sigma).
Cells were then washed again with PBS, followed by
fixation and permeabilization, azide-coupling reaction
and DAPI staining. At the end, coverslips were washed
in PBS, and mounted on glass slides with Ibidi Mount-
ing Medium (Ref. 50001, Biovalley).
Photographs of the cells were taken and analyzed as for
the RRS assay. At least 50 non-S-phase cells were randomly
selected, and the average nuclear fluorescent intensity was
calculated.
Results
Targeted regions: design strategy
Our goal was to develop an efficient mutation-screening
process for the diagnosis of patients with phenotypes
suggestive of NER defects. We chose a multiplex amplifica-
tion approach coupled with NGS to focus on genomic
sequencing of all NER genes known to be involved in
human diseases at the time the study was designed, as well
as on their direct interactors (Table 2). Three genes located
on sex chromosomes (SRY, AMELX and AMELY) were in-
cluded for quality control purposes.
Analysis and evaluation
The procedure was first performed on a cohort of 11
samples, previously tested by Sanger sequencing of
ERCC6(CSB) and/or ERCC8(CSA) genes. Pathogenic
mutations were detected in 5 samples, as well as non-
pathogenic variants which were found in all.
Initially, we tested several combinations using between
one and four patient DNA samples, pooled together on
314 or 316 arrays. Based on these preliminary results,
we then pooled 8 patient DNA samples on a 316 array
for diagnostic testing.
We assessed the sensitivity and specificity of single
nucleotide variation (SNV) detection by comparing NGS
results with allelic states of SNVs detected by Sanger
sequencing of ERCC6(CSB) and ERCC8(CSA) in the 11
samples. Several variation types (missense, nonsense,
splice mutations and small deletion of one base) at dif-
ferent allelic states were tested (Additional file 1). All 63
previously identified single base variations were detected in
their correct heterozygous/homozygous state. A further
94,321 normal ERCC6(CSB) and/or ERCC8(CSA) bases
were also correctly sequenced with no false positives. In
our sample (N = 63 variations, with 100 % correct detection
rate), the probability of a false-negative event can be esti-
mated at 3/N (=5 % with N = 64). This corresponds to an
overall sensitivity of ≥95 %, calculated using the ‘rule of 3’
estimate of power, with respect to sample size [34]. The
overall specificity, calculated by the same method using
data from the 94,321 normal bases, can be estimated at
≥99.99 %.
Finally, analysis of variations in copy number was
assessed using an amplicon-based enrichment NGS tech-
nique, a quantitative method used to compare the number
of reads for each amplicon in each sample of the run [35].
A heterozygous 4.6 Mb deletion of chromosome 10q11,
encompassing the whole ERCC6(CSB) gene, was clearly
detected by this process, as well as by direct observation
of the coverage data using Alamut Visual. In contrast, we
were unable to detect an ERCC6(CSB) deletion limited to
the first two exons of the gene, with this technique (data
not shown).
Results from the 40 patient cohort
We analyzed data obtained from a cohort of 40 consecu-
tive patients referred for suspected Cockayne syndrome
(n = 30), xeroderma pigmentosum (n = 5), UV sensitive
syndrome (n = 2) or COFS syndrome (n = 3). Our tech-
nique allowed us to generate a high-quality sequencing
dataset, with a mean depth of coverage of 944X. On
average, 95 ± 3 % of targeted regions were covered more
than 30X for each patient. Depth of coverage was highly
variable (944 ± 493 X) but always over 172X. Few regions,
(n = 14 out of 452 amplicons, or 3 % of the amplicons)
appeared to be consistently or frequently (>50 % of the
patients) poorly covered (mean coverage < 30X) (Additional
file 2). Of these, the first group are mainly highly GC-rich
regions which are difficult to amplify, and also difficult to
study by capture enrichment processes as demonstrated by
the limited coverage of these regions on the ExAC database.
Other poorly covered regions are low GC-content regions
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with numerous small polyA or polyT tracts. Such homo-
polymer stretches are well known to be prone to high
error rates with Ion Torrent PGM sequencing technology
[36, 37]. An average of 67 ± 12 unfiltered variations per
patient was observed.
We detected clear pathogenic biallelic mutations in 17
of the 40 cases (43 %). No potentially pathogenic variant
could be identified in any of the 16 targeted genes in the
remaining 23 patients (57 %).
Diagnosis of patients with classical phenotypes
Amongst the confirmed mutation group (17 patients), two
thirds (n = 11) displayed a molecular diagnosis correspond-
ing to the classical clinical presentation. Concerning CS,
four patients (# 1 to 4) showed biallelic mutations in the
ERCC6(CSB) gene and three patients (# 5 to 7) in the
ERCC8(CSA) gene. They all display a classical Cockayne
phenotype with growth failure, microcephaly, intellectual
disability, pyramidal and extra-pyramidal signs and neuro-
sensorial impairment (Table 3). Several novel mutations
were found in these two genes including 2 frameshift, 3
splicing and 1 missense mutation (Table 4). None of these
variants were present in the EVS or ExAC databases. The
novel ERCC8(CSA) missense variant, c.356C >T p.Ser119-
Leu, involved an amino-acid located in a WD40 repeat
domain. It is predicted to be deleterious by SIFT, probably
damaging by PolyPhen2 and disease causing by Mutation-
Taster. Whilst the parents were not available for segregation
analysis (patient #6), this missense mutation is located in a
region in which many other clearly pathogenic missenses
have been reported. The second mutation in our patient is
a splice consensus mutation with a high pathogenicity
potential.
Concerning XP, analysis of a group of six patients
from four families coming from Northern Spain (Can-
tabria, n = 1, Basque Country, n = 5) allowed us to iden-
tify a founder mutation in the POLH gene (Additional
file 2). All patients except for one have developed one
or several skin cancers (melanomas, basocellular car-
cinomas and epidermoid carcinomas) with an onset of
between 15 and 41 years of age. Four of the patients experi-
ence photophobia. Increased number of lentigines (n = 2/6)
and exaggerated and prolonged sunburn response (n = 2/6)
are also described. One patient suffers from hearing prob-
lems. No other symptoms have been reported. All patients
exhibited a normal NER level after UV irradiation, even on
UDS or RRS assay. This is a hallmark of XP variant (XP-V),
a disease linked to the POLH gene. NGS was performed on
a single patient from each family (patients # 10 to 13). In 3
of these 4 patients, we identified a homozygous POLH
variation at the canonical donor site of intron 6, c.764 +
1G >A. Parental segregation confirmed the heterozygous
carrier status of the parents in one family. The last patient
(patient # 10), was compound heterozygous for the same
POLH splicing mutation and for a novel POLH stop
mutation: c.1445C >A p.Ser482*. cDNA studies on the
homozygous patients revealed two truncated transcripts
(Additional file 3): the first splice form, with the greatest
expression, uses a cryptic splice donor site, 42 bp upstream
from the end of exon 6. The resulting in-frame deletion
(r.723_764del42; p.Ser242_Ile255del14) leads to shortening
of the polymerase eta protein by 14 amino acids. The
second splice variant has a deletion of the entire exon 6
(104 bp) (r.661_764del104) expected to produce a 221-
amino-acid truncated protein (p.Val221Profs*2). Whereas
the c.764 + 1G >A mutation is largely unknown (described
once in the ExAC database, in one out of 11,564 alleles
from a Latino population), the c.764 + 1G >C mutation has
been described in patient XP31BE [38] with exactly the
same abnormal transcripts. As expected in XP-V cell lines,
fibroblasts collected from our Spanish patient exhibited a
specific reduction in post-UV survival in the presence of
caffeine (data not shown). Haplotype analysis using the
Illumina HumanOmniExpress-24 SNP chip showed a com-
mon homozygous haplotype of 975 kb encompassing the
POLH gene in the patients of families # 11, 12 and 13
(Additional file 4). The patient with compound heterozy-
gosity presented a genotype over the 257 SNPs in the inter-
val completely compatible with the founder haplotype.
Uncommon diagnoses established by targeted NGS
The remaining third of cases from our confirmed mutation
group (n = 6 out of 17 patients) displayed atypical findings
such as mild and incomplete symptoms, combined pheno-
types or involvement of extremely rarely implicated genes.
Of these cases, we identified two close ERCC8(CSA)
missense mutations in two CS patients showing incomplete
or mild symptoms. The younger patient (#8) is a 16 year
old boy presenting with an incomplete clinical picture with
normal growth (25th centile), slight intellectual deficiency,
behavioral difficulties, congenital unilateral deafness, pro-
gressive enophthalmia and cutaneous photosensitivity
(Additional file 5). The older patient (#9), a 26-year-old
man, was referred for small stature, microcephaly, congeni-
tal deafness, learning difficulties and photosensitivity associ-
ated with truncal cutaneous spots and cerebellar atrophy
(Additional file 5). Both patients, born to consanguineous
parents, are homozygous carriers of a missense variant,
respectively c.730C >T p.His244Tyr for patient #8 and
c.793A >C p.Thr265Pro for patient #9. These variations,
which are absent from the EVS and ExAC databases,
involve conserved amino-acids localized in the same func-
tional WD40 domain and are predicted as deleterious by
Sift and PolyPhen2. Segregation studies have confirmed the
carrier status of the parents in both families. The two
healthy siblings of patient #8 and four healthy siblings of
patient #9 were either heterozygous carriers of the familial
missense variant or homozygous for the wild type allele.
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Table 3 Clinical description, molecular and cellular results of the 40 NER-defective patients studied by NGS
Patient
#
Gender Clinical
indication
Intellectual
disability/
psychomotor
delay
Growth
failure
Micro-
cephaly
Photo-
sensitivity
Neuro-
sensorial
impairement
Cancer RRS UDS NGS
diagnosis
Mutated
gene
Mutations
(c.)
Mutations
(p.)
Parentation
segregation
1 F CS + + + + + - ↓ NA + ERCC6(CSB) c.[(?_-164)_(−15+44
+1_136-1)];[2047C>T]
p.[?];[Arg683*] + (only
mother)
2 M CS + + + + + - ↓ NA + ERCC6(CSB) c.[2599-
26A>G];[4115delG]
p.[Met867Thrfs*14];
[Gly1372Glufs*22]
+
3 M CS + + + NA + - NA NA + ERCC6(CSB) c.[2060C>T];[3862C>T] p.[Ser687Leu];[Arg1288*] +
4 M CS + + NA + - - ↓ N + ERCC6(CSB) c.[543G>T];[543
+4delA]
p.[Lys181Asn];[?] +
5 F CS + + + + + - NA NA + ERCC8(CSA) c.[927delT];[1041
+1G>T]
p.[Phe309Leufs*19];[?] +
6 F CS + + + ++ + - ↓ N + ERCC8(CSA) c.[356C>T(;)618-1G>A] p.[Ser119Leu(;)?] NA
7 M CS + + + + - - ↓ NA + ERCC8(CSA) c.[611C>A];[1122
+1delG]
p.[Thr604Lys];[?] + (only
mother)
8 M CS + - - + + - I N + ERCC8(CSA) c.[730C>T];[730C>T] p.[His244Tyr];[His244Tyr] +
9 M CS + + + + + - I NA + ERCC8(CSA) c.[793A>C];[793A>C] p.[Thr265Pro];
[Thr265Pro]
+
10 F XP - NA - + - + N N + POLH c.[764
+1G>A(;)1445C>A]
p.[?(;)Ser482*] NA
11 F XP - NA NA + - + N N + POLH c.[764+1G>A(;)764
+1G>A]
p.[?(;)?] NA
12 F XP - NA - + - + N N + POLH c.[764+1G>A(;)764
+1G>A]
p.[?(;)?] NA
13 M XP - NA NA + NA + N N + POLH c.[764+1G>A];[764
+1G>A]
p.[?];[?] +
14 M CS + - + ++ + - NA ↓ + ERCC2(XPD) c.[1847G>C];[2047C>T] p.[Arg616Pro];[Arg683Trp] + (only
mother)
15 F UVSS - - - ++ - - NA ↓ + ERCC2(XPD) c.[2047C>T];[2047C>T] p.[Arg683Trp];
[Arg683Trp]
+
16 F CS + + + + - - ↓ ↓ + ERCC5(XPG) c.[2200-
10C>G];[2200-
10C>G]
p.[?];[?] +
17 M UVSS - - - ++ + - ↓ ↓ + ERCC3(XPB) c.[296T>C(;)325C>T] p.[Phe99Ser(;)
Arg109*]
NA
18 M CS + + + - + - NA NA -
19 F CS + + + NA + - N ↓ -
20 F XP + + NA ++ + - NA NA -
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Table 3 Clinical description, molecular and cellular results of the 40 NER-defective patients studied by NGS (Continued)
21 M CS + + + NA - - N N -
22 F CS + + + - + - I N -
23 M CS + + + NA + - I NA -
24 F CS + + - - - - N N -
25 M CS + + + - - - N NA -
26 F CS + + + - - - N N -
27 M CS - + + - + - NA NA -
28 M COFS NA + + NA + - N N -
29 M CS + + + + + - NA NA -
30 F CS + + + + + - N ↓ -
31 M CS + + + - + - NA NA -
32 F CS + + + + - - ↓ N -
33 M CS + + + - - - N N -
34 F CS + + + - - - NA NA -
35 F CS + + + - + - NA NA -
36 F CS + + + - + - NA NA -
37 M CS + + + - + - NA NA -
38 F CS + + + NA + - NA NA -
39 F COFS NA + + NA NA - NA NA -
40 M COFS NA + + NA NA - N I -
Undescribed variations are in bold. Variations are described according to the latest nomenclature conventions described in HGVS. I: inconclusive results, N: normal; NA: not available; RRS: recovery of RNA synthesis;
UDS: unscheduled DNA synthesis
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Table 4 Novel variations identified in ERCC6(CSB), ERCC8(CSA), ERCC2(XPD), ERCC3(XPB) ERCC5(XPG) and POLH genes
Gene DNA
variant
cDNA variant Protein Type (DNA) Localization Variant
predicted
effect
Functionnal
domain
Frequency
in EVSdb
Frequency
in ExACdb
Prediction among SIFT
and PolyPhen 2 and
Mutation Taster
Patient
#
ERCC6(CSB) c.543G>T r.423_543del (exon 3
deletion)
p.Lys181Asn Substitution exon 3 Missense
+ splicing
- NF NF D, PD, DC 4
c.4115delG - p.Gly1372Glufs*22 Deletion exon 21 Frameshift - NF NF - 2
ERCC8(CSA) c.356C>T - p.Ser119Leu Substitution exon 4 Missense WD40 NF NF D, PD, DC 6
c.730C>T - p.His244Tyr Substitution exon 9 Missense WD40 NF NF D, PD, DC 8
c.793A>C - p.Thr265Pro Substitution exon 9 Missense WD40 NF NF D, PD, DC 9
c.927delT - p.Phe309Leufs*19 Deletion exon 10 Frameshift - NF NF - 5
c.1041
+1G>T
Not tested p.? Substitution intron 10 Splicing - NF NF - 5
c.1122
+1delG
Not tested p.? Deletion intron 11 Splicing - NF NF - 7
ERCC3(XPB) c.325C>T - p.Arg109* Substitution exon 3 Nonsense - 0.000462 0.000478 - 17
ERCC3(XPB) c.2200-
10C>G
r.2199_2200ins2200-
9_2200-1 (partial
insertion of intron 9)
p.Glu734_Thr1186delinsIleLeu* Substitution intron 9 Splicing - NF NF - 16
POLH c.764
+1G>A
r.723_764del42 (partial
del exon 6)
p.Ser242_Ile255del14 Substitution intron 6 Splicing - NF 8.241e-06 - 10, 11,
12, 13
p.Val221Profs*2
r.661_764del104 (del
exon 6)
POLH c.1445C>A - p.Ser482* Substitution exon 11 Nonsense - NF NF - 10
D deleterious, DC disease causing, EVSdb Exome Variant Server database, ExACdb Exome Aggregation Consortium database, NF no frequency data available, PD probably damaging
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Studies of ERCC8(CSA) mRNA in patient #9 found a
normal-sized transcript with the homozygous p.Thr265Pro
missense mutation. RRS functional assay was inconclusive
in these two cases: repeated experiments showed variable
results which prevented us from drawing any formal con-
clusions about the efficiency of TC-NER in these patients
under experimental conditions (data not shown).
One patient referred for CS and one for UVSS were
linked to the ERCC2(XPD) helicase gene, with a final diag-
nosis of XP/CS and XP respectively. Patient #14 was the
first child of young unrelated healthy parents. His birth
weight was 2760 g (10th centile), length was 47.5 cm (5th
centile) and his head circumference was 33 cm (5th centile).
He was referred for early and severe photosensitivity, learn-
ing difficulties, peripheral neuropathy and deafness. At the
age of 14, he presented microcephaly (head circumference:
50.5 cm (below the 3rd centile)) without growth failure
(height: 162 cm (mean) and weight: 44.4 kg (25th centile)).
No evidence of calcification or leucodystrophy was revealed
on brain imaging. No cutaneous malignancies were de-
scribed at the age of 16. The patient has a younger sister
(15 year old) who presents a less severe phenotype without
microcephaly or neuropathy, but with learning disabilities
and mild photosensitivity. Surprisingly, we identified two
compound heterozygous missense variations (already de-
scribed) in ERCC2(XPD): c.1847G >C and c.2047C >T.
These lead respectively to the protein changes p.Arg616Pro
and p.Arg683Trp. The p.Arg683Trp mutation was inher-
ited from the mother, the father was not tested. The af-
fected sister shares the same genotype as patient #14. Both
variations, involving highly conserved amino-acids and
located in a helicase domain, have been previously reported
in either XP or in TTD patients [39, 40]. Our patient
shared the same genotype as the XP17PV patient present-
ing with XP and mild neurological abnormalities [40]. His
first tumor appeared at 22 years of age. The second
ERCC2(XPD) patient of the cohort (#15) is the first child of
consanguineous healthy parents, referred by the dermatolo-
gist for UVSS. She presents severe photosensitivity with
normal growth and psychomotor development. No cutane-
ous cancer was described at the age of 4. She was found to
be homozygous for the common ERCC2(XPD) missense
mutation, c. 2047C >T p. Arg683Trp, as was her affected
younger sister. The parents are heterozygous carriers of the
mutation. Both patients display a severely decreased UDS.
A further CS patient was diagnosed with combined
XP/CS, linked to the rarely involved ERCC5(XPG) gene.
Patient #16 was the first child of young healthy parents.
No consanguinity was known but the parents came from
very close villages. The patient was born at term. Her
birth weight was 2700 g (25th centile), length was 51 cm
(mean) and her head circumference was 31 cm (below
3rd centile). Apgar score was 10. The patient was evalu-
ated at the age of 4 years and 4 months. At that time,
she was 81 cm tall, weighed 7 kg, and had a head cir-
cumference of 35 cm (all well below the 1st centile). She
displayed delayed developmental milestones (she sat at the
age of one year, walked when she was 2 years old and spoke
single words at the age of 3.5). She exhibited an abnormal
ataxic gait. She also had deep set eyes and signs of retinal
pigmentary degeneration. Auditory assessment was normal.
She had cutaneous photosensitivity associated with dry skin
and numerous pigmented naevi. Her brain MRI showed
de-myelination of the white matter (Additional file 6). Liver
enzymes were slightly elevated (SGOT= 43 U/l; SGPT=
99U/l). Both RRS and UDS were severely decreased. We
identified a novel homozygous ERCC5(XPG) variation at
the acceptor site of intron 9, c.2200-10C >G, the first spli-
cing mutation described in this gene. Both parents were
found to be heterozygous carriers of the variant. cDNA
studies revealed a significant biological impact with no
normal transcript but with several aberrant species leading
to early protein termination. The major transcript included
the last 9 bp of intron 9 between exon 9 and 10, leading to
a premature stop codon (p.Glu734_Thr1186delinsIleLeu*).
As expected in ERCC5(XPG) XP/CS cell lines [41], the
patient’s fibroblasts exhibited a specific reduction of post-
UV survival in the presence of methylene blue (data not
shown).
The last atypical result involved a teenager referred
for UVSS who was found to carry mutations in the
ERCC3(XPB) gene. To date, eight different mutations in
nine patients from six families have been reported. Patient
#17 displayed severe and early-onset photosensitivity with
erythema and progressive lentigines on exposed areas
(Additional file 7). No skin cancer was described at the age
of 13. General health was good, with normal growth and
psychomotor development. Moderate unilateral hypoacou-
sia was described. The patient has a younger brother who
suffers from less severe photosensitivity. As expected, both
UDS and RRS were severely decreased. We identified two
close heterozygous substitutions in ERCC3(XPB): c.296 T >
C and c.325C >T, leading to the p.Phe99Ser missense
mutation and to the p.Arg109* nonsense mutation respect-
ively. As both mutations were never observed on the same
NGS read (Additional file 7), we can consider that they are
located in trans, even without analyzing parental samples
(which are unavailable). The p.Phe99Ser missense mutation
has been previously reported in association with the c.471
+ 1G >A p.K157insTSDS* splicing mutation in two mild
XP/CS siblings [42] and with the c.1273C >T p.Arg425*
nonsense mutation in two XP siblings [43]. The p.Arg109*
nonsense mutation has never been described in NER
patients but is present in the EVS and ExAC database at a
very low frequency (0.08 % in Europeans). This appar-
ent discrepancy between the rarity of reported cases of
ERCC3(XPB) mutations and the relatively high fre-
quency of the p.Arg109* mutation in Europeans raises
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the question of possible fetal lethality when truncated
mutations in this gene are present on both alleles.
This hypothesis is consistent with the absence of such
cases in the litterature.
Discussion
Our aim was to develop a single and efficient mutation-
screening process for NER defects and to improve our
understanding of the clinical spectrum of these overlap-
ping and sometimes combined disorders. We performed
targeted next generation sequencing of 16 NER genes in
a cohort of 40 consecutive patients presenting with
phenotypes suggestive of DNA repair defects. Our find-
ings confirm the efficiency of this process, which is able
to simultaneously analyze 95 ± 3 % of targeted regions in
8 patients in a single run. Coverage is sufficiently sensi-
tive (overall sensitivity ≥95 % in the preliminary cohort)
to guarantee reliable detection of heterozygous variants
and small indels. Whole gene deletion is also detectable,
but the method is currently not sensitive enough (in our
hands), to detect smaller heterozygous deletions (for
example, a heterozygous deletion of the first two exons
of the ERCC6(CSB) gene was not detected). This could
be explained by the heterogeneity of the samples tested
in one run (various sample types analyzed such as blood
or fibroblast cultures, various DNA extraction methods
used), as well as by the small number of patients per run,
preventing normalization of depth of coverage on a large
cohort. These limitations are unfortunately difficult to
improve upon. Nevertheless, missing heterozygous CNV
is less harmful in the context of exclusive autosomal
recessive disorders than in dominant diseases. Presence of
a CNV could indeed be considered when a single point
mutation is found, then checked by a quantitative assay.
We identified causative mutations in 43 % of the cohort
(17 out of 40 patients). This approach permits rapid con-
firmation of the molecular diagnosis for classical presenta-
tions of CS and XP. It has established the diagnosis in
seven typical CS cases (patients # 1 to 7) with pathogenic
mutations in either ERCC6(CSB) or ERCC8(CSA), and in
four XP cases (patients # 10 to 13) with mutations in
POLH. The technique is also reliable in cases with uncom-
mon phenotypes (combined features or unusually mild
symptoms or very rarely involved genes). For example, two
of our patients initially referred for CS have a final diagnosis
of XP-CS complex (patient #14 mutated in ERCC2(XPD)
and patient #16 mutated in ERCC5(XPG)). Two further
cases referred for UVSS had mutations in XP genes (patient
#15 in ERCC2(XPD) and patient #17 in ERCC3(XPB)).
These results clearly illustrate the challenge that clinical
diagnosis of NER defects presents, and entirely justifies the
multi-gene approach in molecular diagnosis. The diag-
nosis of NER diseases usually relies on established clin-
ical criteria [7, 44, 45] but these criteria are often only
fulfilled in patients at a relatively advanced stage of the
disease. Clinical diagnosis is therefore difficult in young
or late-onset cases that do not entirely fit the criteria.
NGS is a particularly good alternative for confirming
such cases at an early stage. The benefits of early diag-
nosis are well known in NER defects, for example, in
order to prevent cutaneous cancer in XP and to delay
sensory impairments and manage feeding difficulties in
CS. Appropriate genetic counseling is beneficial for
family members in all cases.
As expected, the majority of causative mutations iden-
tified in the CS patients were found to be located in the
two main CS genes, ERCC6(CSB) (patients #1 to 4) and
ERCC8(CSA) (patients #5 to 9). We detected eight novel
mutations in these genes, four missenses predicted to be
pathogenic, two frameshift mutations by single nucleotide
deletions, and two mutations in splicing donor consensus
sequences (Table 4). Including the last review [44] as well
as recent case reports [46–51], the number of known muta-
tions now rises to 86 for ERCC6(CSB) and 38 for
ERCC8(CSA).
We also describe the first splicing mutation in
ERCC5(XPG) in an XP-CS patient (patient #16, homo-
zygous for the c.2200-10C > G mutation). Biallelic mu-
tations in the ERCC5(XPG) gene have previously been
associated with XP (group G), CS, XP-CS and COFS
[14, 16]. In the NER pathway, the XPG endonuclease
performs a 3’ incision of the abnormal strand and stabi-
lizes the basal transcription factor TFIIH. Patients have
either truncating or point mutations that abolish TFIIH
interaction, with truncating mutations being associated
with the more severe phenotypes. So far, around 20
patients with a defect in the ERCC5(XPG) gene and 30
different disease-causing mutations have been described
worldwide [14, 16, 52, 53]: 20 nucleotide substitutions (9
nonsenses and 11 missenses), 9 deletions of only 1 to 4
bases, 1 duplication and 1 large deletion [16]. We identified
a homozygous splicing mutation without any expression of
the normal transcript in cutaneous fibroblasts, leading to a
severe XP-CS phenotype. The patient, initially referred for
suspected CS, has a more complex diagnosis. This molecu-
lar finding radically changes the clinical management,
which will include cutaneous cancer prevention and genetic
counseling for the family.
The ERCC3(XPB) gene is even more rarely involved in
human diseases. Coding a helicase, it is mutated in only
nine reported patients from six families, with remarkable
phenotypic heterogeneity: XP/CS (5 patients from 4
families), relatively mild XP without CS (2 siblings) and
TTD (2 siblings) [43]. To date only eight different muta-
tions have been identified in ERCC3(XPB): 2 missense
mutations, 4 truncating mutations (nonsense mutations,
deletion or insertion of one base pair) and 2 splicing
mutations [43]. Genotype/phenotype correlation studies
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of the short ERCC3(XPB) patient cohort have suggested
that partially active missense mutations may explain symp-
toms in milder patients, whilst severe XP/CS complex
patients have nonsense or consensus splice mutations with
low levels of altered XPB proteins. Patient #17, a teenager
referred for UVSS due to severe and early onset photosensi-
tivity (without skin malignancy or neurological impairment)
(Table 3), was found to be compound heterozygous for the
known p.Phe99Ser mutation and for a novel nonsense
p.Arg109* mutation. A similar genotype was found in two
XP siblings, XP33BR and XP1SA, which carry p.Phe99Ser
and p.Arg425* mutations [43]. ERCC3(XPB) mutations
have been reported in XP/CS, XP alone and TTD patients,
but never in UVSS patients as of yet. As our patient is only
13 years old, skin malignancy may still develop. Patients
XP33BR and XP1SA which carry a similar genotype, both
had multiple basal cell carcinomas, the first of which was
diagnosed at 28 and 29 years old [43]. Long term follow up
of our patient is necessary in order to test the hypothesis
that the clinical spectrum of ERCC3(XPB) mutations ex-
tends to UVSS. As described previously, once again the
molecular diagnosis leads to appropriate clinical follow-up.
Our cohort also included six XP patients from 4 unre-
lated families coming from the Basque country and
surrounding area in Northern Spain. Surprisingly, all cases
had mutations in the same gene, POLH, encoding the
translesion DNA synthesis polymerase eta. Biallelic muta-
tions in this gene have previously been associated with
Xeroderma-Pigmentosum Variant (XP-V), which is distinct
from classical XP due to the absence of insufficient DNA
repair measured either by UDS or RRS. XP-V patients also
have a relatively milder phenotype with late onset symp-
toms and delayed progression [54]. More than 60 muta-
tions have been identified in the POLH gene, in cell lines
derived from XP-V patients from different geographic
locations [54]. The four patients from our cohort and their
two siblings shared the same previously undescribed
splicing mutation (NM_006502.2:c.764 + 1G >A). This
was either in the homozygous form (5 out of 6 patients)
or in combination with a novel nonsense mutation
(NM_006502.2:c.1445C > A, p.Ser482*) (in one patient).
Haplotype analysis showed a founder haplotype of 975 kb
encompassing the POLH gene in the 4 families that were
investigated (3 homozygous, 1 compound heterozygous).
This suggests that a common ancestor carrying the muta-
tion lived approximately 500–1000 years ago (using com-
parison calculations for a similar sized founder haplotype)
[55]. Similar founder mutations in the POLH gene have
been reported in other populations such as in Japan,
Korea [38, 56] and Tunisia [57]. Such founder effects have
previously been described in patients from the Basque
country for several other diseases such as Parkinson disease
[58], fatal familial insomnia [59] and limb-girdle muscular
dystrophy type 2A [60]. These findings are consistent with
the fact that this population has been relatively isolated in
terms of genetic mixing in the past. Consequently, we
suggest systematic screening for this mutation in all mild
XP patients coming from the Basque country and its
surrounding area.
Under our experimental conditions, classical functional
assays failed to clearly identify two mild CSA patients (# 8
and 9), who have proven pathogenic mutations in the same
WD40 proteic domain. We suspect that fluorescent RRS
assay may overlook mild CS cases, especially when associ-
ated with missense mutations. A different patient carrying a
homozygous missense mutation in the same domain was
reported to have low RRS, but this was associated with a
more severe type I clinical phenotype (patient 08STR2
[25]). In the few previously reported cases of mild late-
onset CS, decreased RRS has always been an associated
finding [25, 45, 61–69]. However, the classical diagnostic
procedure for CS usually recommends performing molecu-
lar sequencing only after identification of a functional
defect in the RRS, and thus atypical CS patients with
normal or inconclusive RRS may be missed. We believe
that these results should be included in the decision making
tree for diagnosis of NER-diseases. In the flowchart pro-
posed by Jia N et al., the authors suggest performing UDS
and RRS assays prior to molecular sequencing (either by
the Sanger method or NGS) [70]. Our experience suggests
that strong clinical suspicion should prompt molecular
investigations. We advocate performing cellular and mo-
lecular tests in parallel, as in most cases cellular tests still
remain important for correct interpretation of nucleotide
variants found by NGS.
Finally, no potentially pathogenic variants were identified
in 23 patients included in the cohort (57 %). All except for
one was referred for CS or COFS syndrome. Gap filling by
Sanger sequencing of the two most commonly involved
genes ERCC6(CSB) and ERCC8(CSA) did not reveal any
anomalies. This relatively high rate of undiagnosed patients
may be explained in part by the fact that 15 % of the cohort
(6 out of 40 patients) had already been explored by Sanger
sequencing of both ERCC6(CSB) and ERCC8(CSA) genes.
Such “prescreening” artificially decreases the rate of positive
diagnoses. Moreover, the 40 patients included in the cohort
were not selected to fulfill the criteria of NER diseases
precisely. Rather, they represent the day to day cases
referred to our laboratory, with many patients presenting
non-specific symptoms such as microcephaly or intellectual
disability. Widening the inclusion criteria allows for diagno-
sis in patients who do not present all the classic diagnostic
features, but it also leads to a lower rate of positive diag-
noses overall. Most of these negative results occur in
patients who are probably not true CS patients, and
further molecular investigations are needed in order to
establish a differential diagnosis. In one case (patient #
32), the phenotype was evocative of a DNA repair defect
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measured by cellular tests. This case highlights the limits
of our targeted approach, as pathogenic mutations could
be localized in non-targeted regions such as promoters or
deep intronic regions. Such mutations are indeed known
in the ERCC8(CSA) gene, with the example of the deep
intronic c.173 + 1046A >G mutation [25]. While cDNA
sequencing of ERC6(CSB) and ERCC8(CSA) genes did not
retrieve any abnormality in patient #32, other NER tran-
scripts have not been studied. Another explanation could
be the presence of a small copy number variation (CNV),
barely detectable by multiplex-based NGS strategies.
Finally, a non-targeted gene could be involved in this
patient. At least two new genes have been documented in
NER disorders since our study was designed. A missense
mutation in the proliferating cell nuclear antigen (PCNA),
an essential DNA replication accessory protein, was iden-
tified in a single family with four patients sharing pheno-
typic similarities to XP, CS and also ataxia telangiectasia
(AT) [71]. In cells from affected individuals, both UDS
and RRS were reproducibly decreased. A family with a
novel X-linked form of non-photosensitive TTD was also
recently described, with a nonsense mutation in a gene of
unknown function, RNF113A [72]. Whereas the targeted
sequencing approach is the simplest tool for analyzing the
genetic variants of a focused panel of genes via NGS, it
will miss newly identified genes and prevents the re-
analysis of data. Exome or full-genome strategies are more
exhaustive alternatives, and are recommended in these
patients. Such approaches have been succesfully used or
suggested for the diagnosis of XP [73, 74].
Conclusions
Targeted NGS of 16 genes involved in the NER pathway
has been demonstrated to be an efficient alternative to
the sequential Sanger approach for the molecular diag-
nosis of patients with a suspected NER defect, with a
positive diagnosis rate of 43 %. We believe that this
novel approach is the most appropriate solution to the
diagnostic challenge presented by patients with com-
bined specific neurological, dermatological and growth
characteristics. This approach enables rapid confirm-
ation of the molecular diagnosis in classical presenta-
tions of CS and XP. It can also be used to determine
atypical phenotypes with combined features or very mild
symptoms. Targeted NGS should be used in addition to
DNA repair functional tests and precise clinical assess-
ment in order to allow rapid, thorough and cost-
effective diagnosis in patients with NER-defects.
Additional files
Additional file 1: Spectrum of previously identified variations within
the validation cohort of 11 patients. 11 patients already tested by Sanger
sequencing of ERCC6(CSB) and/or ERCC8(CSA) genes were explored by
targeted NGS strategy. All 63 previously identified single base variations
were identified in their correct heterozygous/homozygous state. A
heterozygous 4.6 Mb deletion of chromosome 10q11, encompassing the
whole ERCC6(CSB) gene, was clearly detected but the method was not
sensitive enough to detect an ERCC6(CSB) deletion limited to the first two
exons of the gene. (XLSX 14 kb)
Additional file 2: Poorly covered amplicons (mean coverage < 30X).
Some amplicons appeared to be consistently poorly covered (in all
patients of the cohort); others appeared frequently poorly covered
(in more than 50 % of the patients) (XLSX 13 kb)
Additional file 3: Novel POLH splice mutation in non-related XP-variant
patients. A: Pedigrees of the 4 XP-variant families coming from Northern
Spain and mutated in the POLH gene. The arrows indicate the four patients
studied by NGS. Patients #11, 12 and 13 were homozygous for the splice
mutation c.764 + 1G > A whereas patient #10 was compound heterozygous
for mutations c.764 + 1G > A and c.1445C > A (p.Ser482*). B: RT-PCR using
RNA from patients #10 and 11, with forward primer in exon 5 and reverse
primer in exon 8, showed a single 365 bp band in normal cells and two
bands at323 bp and 261 bp in the homozygous patient #11. The diagram
indicates partial deletion (42 bp) of exon 6 in the type I splice variant and
deletion of the entire 104 bp of exon 6 in the type-II splice variant. The
normal transcript was the major transcript in the heterozygous patient #10,
with a fain band corresponding to the type I splice variant. (PPTX 92 kb)
Additional file 4: POLH founder mutation in Northern Spain. Haplotype
analysis was performed on the 6 XP-variant patients coming from Northern
Spain with mutations in the POLH gene (chr6:43,543,878-43,588,260[hg19]).
Despite a genome wide study using the Illumina HumanOmniExpress-24
SNP chip, the table focuses on the SNP localized in the vicinity of the POLH
gene on chromosome 6 (between 42,000,000 and 44,000,000). Patient #11,
patient #12 and her sister and patient #13 and his sister were homozygous
for the c.764 + 1G > A mutation. Patient #10 was compound heterozygous
c.[764 + 1G > A(;)1445C > A]. Parents of patient #13 were heterozygous
carriers of the splice mutation. The five homozygous patients share a region
of homozygosity (975 kb) including the POLH gene (from rs3800291 at
position 42,751,457 to rs866236 at position 43,726,956). The compound
heterozygous patient #10 and the carrier parents have at least one allele in
common with the founder haplotype all along the 975 kb region.
(XLSX 46 kb)
Additional file 5: Clinical pictures of patients #8 (A) and #9 (B) (mutated in
ERCC8(CSA)). (PPTX 403 kb)
Additional file 6: Clinical pictures and brain MRI of patients #16
(mutated in ERCC5(XPG)). Sagittal T1 and axial T2-Flair (PPTX 970 kb)
Additional file 7: Clinical picture and molecular results of patients #17
(mutated in ERCC3(XPB)). A: clinical picture of patient #17. B: Patient #17 reads
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